US 10,376,559 B2
Formulations of vancomycin
Nagesh R. Palepu, Southampton, PA (US); and Philip Christopher Buxton, Uxbridge (GB)
Assigned to SCIDOSE, LLC, Amherst, MA (US)
Filed by SciDose, LLC, Amherst, MA (US)
Filed on Jan. 13, 2017, as Appl. No. 15/405,884.
Claims priority of provisional application 62/279,210, filed on Jan. 15, 2016.
Prior Publication US 2017/0224767 A1, Aug. 10, 2017
Int. Cl. A61K 38/14 (2006.01); A61K 47/10 (2017.01); A61K 47/12 (2006.01); A61K 47/02 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01)
CPC A61K 38/14 (2013.01) [A61K 9/0019 (2013.01); A61K 9/08 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01)] 16 Claims
 
1. A liquid vancomycin-containing composition, consisting of from about 50 mg/mL to about 250 mg/mL of vancomycin or a pharmaceutically acceptable salt thereof, glycerol, a member of the group consisting of lactic acid, lactate or mixtures thereof, a base and a pharmaceutically acceptable fluid containing water, said vancomycin-containing composition having a pH of from about 5.5 to about 6.5 and being suitable for parenteral administration, wherein the amount of glycerol is from about 15 to about 30% (v/v).